Previous work by us and other groups have shown that losartan can ameliorate the manifestation of muscle disease in mouse models of DMD, MDC1A, Marfan syndrome and sarcopenia, likely by attenuating the pro-fibrotic action of TGF-β signalling [10,13,16,30,31]. Here, LAMA2 is linked to Duchenne muscular dystrophy.